Long Terms Follow-Up of the Randomized MetaspHER Study Comparing Intravenous Versus Subcutaneous Trastuzumab in Patients’ With HER2-Positive Metastatic Breast Cancer-Reference-Cited by-同舟云学术

Long Terms Follow-Up of the Randomized MetaspHER Study Comparing Intravenous Versus Subcutaneous Trastuzumab in Patients’ With HER2-Positive Metastatic Breast Cancer

Published:2023-10 Issue:7 Volume:23 Page:e412-e419
ISSN:1526-8209
Container-title:Clinical Breast Cancer
language:en
Short-container-title:Clinical Breast Cancer

Author:

Pivot Xavier^ORCID,Spano Jean-Philippe,Espie Marc,Jouannaud Christelle,Pottier Valerie,Moreau Laura,Extra Jean Marc,Lortholary Alain,Rivera Pascale,Spaeth dominique,Mouri Zahira,Tariket Fella,Dupin Julien,Berthois Aurelien,Ionescu-Goga Miruna,Ferhat Abdennour,Cottu Paul,Gligorov Joseph

Funder

F. Hoffmann-La Roche

F. Hoffmann-La Roche Ltd

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference10 articles.

1. Comparison of subcutaneous and intravenous administration of trastuzumab: a phase I/Ib trial in healthy male volunteers and patients with HER2-positive breast cancer;Wynne;J Clin Pharmacol,2013

2. Comparative pharmacokinetics of subcutaneous trastuzumab administered via handheld syringe or proprietary single-use injection device in healthy males;Wynne;Cancer Chemother Pharmacol,2013

3. Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial;Ismael;Lancet Oncol,2012

4. Subcutaneous vs intravenous trastuzumab for patients with ERBB2-positive early breast cancer: final analysis of the HannaH phase 3 randomized clinical trial;Jackisch;JAMA Oncol,2019

5. Patients' preference of trastuzumab administration (subcutaneous versus intravenous) in HER2-positive metastatic breast cancer: results of the randomised MetaspHER study;Pivot;Eur J Cancer,2017

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Subkutanes Trastuzumab beim metastasierten Mammakarzinom;TumorDiagnostik & Therapie;2024-03-27

2. Subkutanes Trastuzumab beim metastasierten Mammakarzinom;Senologie - Zeitschrift für Mammadiagnostik und -therapie;2024-03

3. Subkutanes Trastuzumab beim metastasierten Mammakarzinom;Geburtshilfe und Frauenheilkunde;2024-01

4. Subcutaneous Trastuzumab: An Observational Study of Safety and Tolerability in Patients With Early HER2‐Positive Breast Cancer;International Journal of Breast Cancer;2024-01